TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$9.86

06 Dec
2023

0.110

OPEN

$9.75

1.13%

HIGH

$9.93

800,212

LOW

$9.61

TARGET
$14.00 42.0% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx - 33.5 21.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 45.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 20182019202020212022
EPS Basic xxxxxxxxxxxx-33.5
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx160.1 M
Book Value Per Share xxxxxxxxxxxx25.3
Net Operating Cash Flow xxxxxxxxxxxx-64.0 M
Net Profit Margin xxxxxxxxxxxx-65.01 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20182019202020212022
Return on Capital Employed xxxxxxxxxxxx-253.34 %
Return on Invested Capital xxxxxxxxxxxx-221.73 %
Return on Assets xxxxxxxxxxxx-56.20 %
Return on Equity xxxxxxxxxxxx-253.34 %
Return on Total Capital xxxxxxxxxxxx-153.82 %
Free Cash Flow ex dividends xxxxxxxxxxxx-71.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20182019202020212022
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx10 M
Total Debt xxxxxxxxxxxx10 M
Goodwill - Gross xxxxxxxxxxxx6 M
Cash & Equivalents - Generic xxxxxxxxxxxx116 M
Price To Book Value xxxxxxxxxxxx28.75

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20182019202020212022
Capex xxxxxxxxxxxx13.9 M
Capex % of Sales xxxxxxxxxxxx8.66 %
Cost of Goods Sold xxxxxxxxxxxx131 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx103 M
Research & Development xxxxxxxxxxxx58 M
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

28/07/2023

1

Buy

$14.00

41.99%

UBS hosted a conference call with Telix Pharmaceuticals and management suggested TLX250-CDx could be as big as, or bigger than, Illuccix in eventual sales.

In short, potential sales of TLX250-CDx could exceed $1bn, while the analyst currently forecasts peak sales of $240m, given forecast usage only allows for a fairly narrow group of patients in the US.

The broker suggests the current share price implies no value is being ascribed to the product and thinks this will change.

The Buy rating and $14 target are maintained.

FORECAST
UBS forecasts a full year FY23 dividend of 0.00 cents and EPS of 24.00 cents.
UBS forecasts a full year FY24 dividend of 0.00 cents and EPS of 42.00 cents.
Access Stockbroker Research History >

TLX STOCK CHART

FNArena News on TLX

1
Australian Broker Call *Extra* Edition – Nov 28, 2023

Nov 28 2023 - Daily Market Reports
2
Rudi’s View: Outlook 2024, Is History Our Guide?

Nov 08 2023 - Rudi's View
3
Australian Broker Call *Extra* Edition – Oct 26, 2023

Oct 26 2023 - Daily Market Reports
4
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

Sep 06 2023 - Rudi's View
5
Australian Broker Call *Extra* Edition – Sep 04, 2023

Sep 04 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
2
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
3
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
4
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
5
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
6
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
7
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
8
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
10
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps